Find a Clinical Trial

Showing 141 - 150 of 182 Trials

A MULTICENTER, OPEN-LABEL PHASE 1/1B/PHASE 2DOSE-FINDING, SAFETY, AND PHARMACOKINETICSTUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYLAURISTATIN E (MMAE) ANTIBODY DRUGCONJUGATE, IN ADVANCED REFRACTORYSOLID TUMORS

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06014658

Population:

Adult

Phase:

I

The purpose of this research is to determine the dose and dosing regimens of an investigational drug, MBRC-101, that are well tolerated, as well as to evaluate its safety in patients with advanced or metastatic solid tumors that have already received conventional therapy. MBRC-101 is not an approved treatment anywhere in the world. “Investigational” means that the drug has not been approved by any government authority responsible for the regulation of new medicines, such as the U.S. Food and Drug Administration (FDA). This is the first time MBRC-101 is being tested in humans. Are...
A First-in-Human Study of Mutant-selective PI3Kα Inhibitor,RLY‑2608, as a Single Agent in Patients with Advanced SolidTumors and in Combination with Endocrine Therapy +/- aCDK4/6 or CDK4 Inhibitor in Patients with Advanced SolidTumors or Advanced

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT05216432

Population:

Adult

Phase:

I

This research study is designed to learn about the safety of an experimental (investigational) drug called RLY-2608, also called the study drug, when given to individuals who have been diagnosed with metastatic (spread to other areas of the body) or unresectable (cannot be removed surgically) cancers and have at least one mutation in a gene called PIK3CA. “Investigational” means that it is not yet known if this drug helps patients, has not been approved by the Food and Drug Administration (FDA) or any other regulatory agency, and is not available for sale as a marketed product...
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Efficacy of YL217 in Patients with Advanced Solid Tumors

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06859762

Population:

Adult

Phase:

I

The main purpose of this study is to evaluate the safety and effectiveness of the study drug, YL217, in different solid tumor types. We also want to learn: ● The dosage of YL217 that can be safely given to humans ● What effect (good or bad) YL217 has on your cancer ● What happens to YL217 once it is in your body (so called pharmacokinetics; PK) ● What YL217 does to your body MediLink Therapeutics has begun a study of an investigational drug (also known as the “study drug”) called YL217 as a possible treatment for CDH17 expressed solid tumors. CDH17 is a type of protein found on...
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy ofLY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing TumorCells, in Participants with Selected Advanced Solid Tumors

Principal Investigator:

Lanyi Nora Chen, MD

Contact Number:

212-342-5162

NCT Number:

NCT07046923

Population:

Adult

Phase:

I

The purpose of this study is to learn about the effects of the study drug, LY4175408, to find the best dose for treating advanced/metastatic (meaning the cancer has spread beyond where it started to other parts of the body) cancers and to see how safe LY4175408 is for patients with advanced/metastatic cancers. LY4175408 is an “investigational” drug in this study because it has not been approved by The United States Food and Drug Administration (FDA), the health authority that gives approval for new medicines in the United States. Are you Eligible? (Inclusion Criteria) Is ≥18...
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT07082920

Population:

Adult

Phase:

I

The purpose of this study is to find a safe dose of investigational study drug, JNJ- 95298177 when given in combination with investigational drug, JNJ-78278343 in patients with prostate cancer. JNJ-78278343 and JNJ-95298177 are not approved by the United States Food and Drug Administration (FDA). The sponsor, Janssen Research & Development, provides the investigational study treatment, called “JNJ-78278343 and JNJ-95298177”. This is the first time that JNJ-78278343 is being used in combination with JNJ-95298177. Are you Eligible? (Inclusion Criteria) At the time of informed...
A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Principal Investigator:

Aya Haggiagi, MD

Contact Number:

212-342-5162

NCT Number:

NCT06860594

Population:

Adult

Phase:

I

Researchers recently found that triapine can make radiation therapy work better against glioblastoma cells and in mice with glioblastoma. Tumors did not grow for a longer time after treatment with triapine along with radiation compared to radiation alone. Triapine has also been tested in people with other types of cancers and has been found to be safe. This study is being done to answer the following question: What is the highest dose of triapine that can be safely and tolerably taken in combination with radiation therapy in patients with recurrent glioblastoma or astrocytoma? We are doing...
A Phase 1, First-in-Human, multicenter, open-label trial ofDS9051b in participants with advanced or metastaticadrenocortical carcinoma (ACC) and metastatic castrationresistantprostate cancer (mCRPC)

Principal Investigator:

Alexander Z. Wei, MD

Contact Number:

212-342-5162

NCT Number:

NCT07189403

Population:

Adult

Phase:

I

he purpose of this trial is to learn more about an investigational drug called DS9051b. DS9051b is an investigational drug that is not Food and Drug Administration (FDA) approved for your disease. This is a first in human study. It is being studied to see if it is safe, and if your disease improves while taking it. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must be able to swallow the study drug - Must not have known gastrointestinal disease or procedure that may interfere with absorption of the study drug
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 asMonotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT07277413

Phase:

I

The purpose of this study is to determine the ideal dose of the study drugs, IDE892 by itself and IDE892 in combination with IDE397, and to find out what effect, good and/or bad, these study drugs may have on your cancer. This will be first human study for IDE892. Both IDE892 and IDE397 has not been approved by the United States (US) Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must be willing and able to provide blood/tumor tissue samples for biomarker testing - Must be able to swallow and retain the study drug
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, inAdvanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations- J5M-OX-JOXA

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06561685

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of an investigational treatment called LY4050784 in subjects with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1. LY4050784 is an investigational (or experimental) drug, taken by mouth that targets a gene called SMARCA2/BRM, and may treat certain cancers. Investigational means neither the FDA nor any other health or regulatory authority in other countries have approved LY4050784. This study will be the first time LY4050784 will be tested in humans. Are you Eligible...
A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination with Anticancer Agents in Patients With Advance Solid Tumors

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06589596

Population:

Adult

Phase:

I

The purpose of this study is to test if the study drug (BGB-58067) alone and the study drug combinations including tislelizumab and chemotherapy (carboplatin, cisplatin, pemetrexed, paclitaxel, nab-paclitaxel, gemcitabine, fluorouracil, leucovorin, irinotecan, and oxaliplatin) are safe and tolerable, test how your body processes the study drug/the study drug combinations, find the safest and most appropriate dose(s) and test if it/they work in patients with advanced solid tumor who have methylthioadenosine phosphorylase (MTAP) deficiency, including those with a loss of MTAP or no MTAP...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages